IPO Boutique Research, Color & More Information for Subscribers
IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis. If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]
IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis. If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]
The biotech barometer may be here. Editas Medicine (Nasdaq: EDIT), a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes, updated terms for its IPO and has scheduled a February 3rd trade date. The interest in this deal is currently very large for a few reasons. For[…]
Wednesday was an ugly day on Wall Street. The Dow tumbled 291 points (-1.62%)…which seemed like a hill of beans compared to the Nasdaq’s 118 point (-2.37%) tumble. What’s concerning to the IPO and secondary market is the sector of stock being hit–technology and biotech company’s. On Wednesday, a deal that was up-sized on two[…]
It’s Thursday, so why not indulge the ‘throw-back’ nature of the day and look at a pair of biotechs from January 2014 that started the Healthcare crazy in the IPO market: Dicerna Pharmaceuticals (Nasdaq: DRNA) and Ultragenyx Pharmaceuticals (Nasdaq: RARE). These were two of 102 biotech deals that came to market in 2014 but the[…]